Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Colorectal Neoplasms 476 Carcinoma, Non-Small-Cell Lung 233 Breast Neoplasms 196 Ovarian Neoplasms 171 Glioblastoma 157 Carcinoma, Hepatocellular 131 Neoplasms 128 Rectal Neoplasms 114 Colonic Neoplasms 110 Neoplasm Metastasis 106 Brain Neoplasms 97 Lung Neoplasms 96 Fallopian Tube Neoplasms 85 Carcinoma, Renal Cell 77 Glioma 69 Pancreatic Neoplasms 54 Liver Neoplasms 44 Melanoma 43 Gliosarcoma 43 Uterine Cervical Neoplasms 40 Adenocarcinoma of Lung 39 Stomach Neoplasms 37 Recurrence 33 Astrocytoma 30 Carcinoma, Ovarian Epithelial 28 Endometrial Neoplasms 27 Triple Negative Breast Neoplasms 26 Kidney Neoplasms 23 Prostatic Neoplasms 22 Esophageal Neoplasms 21

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Feasibility × Bevacizumab × Clear all

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡